Xywav Volumes Jump 12% as Jazz Eyes Aug 25 FDA Decision on Zanidatamab
JAZZ has more than doubled off its 52-week low of $106.65.
Summary
Xywav volumes rose ~12% with active patients reaching ~17,125, driven by adoption in idiopathic hypersomnia, while revenue held steady as high-sodium Xyrem volumes fell ~20% due to generics. This follows strong Q2 oncology sales led by Zepzelca's 42% growth and Ziihera capturing over half the U.S. second-line biliary market. The FDA decision on zanidatamab in gastroesophageal adenocarcinoma is due August 25, a near-term catalyst that could expand the oncology portfolio. The Xywav/Xyrem mix shift shows the branded franchise holding ground against generic erosion, supporting the revenue base ahead of the zanidatamab readout.
At the time of this announcement, JAZZ was trading at $256.60 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $16.7B. The 52-week trading range was $106.65 to $265.05. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Wiseek News.